Efficacy and Safety of Tofacitinib in Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Tofacitinib (CP-690,550) or Adalimumab in Subjects With Active Psoriatic Arthritis
Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT01877668
Protocol ID: A3921091
PrintDownloadOpen Plain Language Summary Result: Click here